Israel Active

Israel’s IIBR-developed BriLife vaccine (see previously - now in Phase 2 testing) has advantages over vaccines such as Pfizer and Moderna. It recognizes the whole of the spike protein and can be easily adjusted to protect against mutations.

Tel Aviv University researchers have developed the triboelectric nanogenerator (TENG) sensor that can be implanted in the body, e.g., under the tip of a severed finger. It connects to another nerve that functions properly and restores tactile sensation to the injured nerve.

Israeli neuroscientists have trained a 50-year-old man, blind from birth, to recognize objects using Israel’s EyeMusic (see previously). The system uses sensory substitution that EyeMusic’s Professor Amir Amedi researched at the Hebrew University (see previously).

Israeli NGO ‘Save a Child’s Heart’ (SACH) has been saving hundreds of lives during the Covid-19 pandemic.

The PlayBeyondBio initiative has selected nine Israeli startups for its program for companies developing solutions for future challenges to healthcare systems. C2i Genomics, Nucleai, Itamar medical, Medial Earlysign, iBex, Octopus.health, Imagene, iCardio.ai and Cordio Medical.

The Israel Institute for Biological Research (IIBR) (see previously) has signed an agreement with Israeli-founded NRx Pharmaceuticals. NRx will complete Phase 2 / 3 trials and commercialize IIBR’s “BriLife” COVID vaccine. Clinical trials will be completed in the Ukraine, Georgia and Israel.

Israel’s Health Ministry has authorized Israel’s healthcare providers to give a third anti-Covid-19 vaccination to adults with impaired immune systems. Israel is the first country to provide boosters to patients who do not develop sufficient antibody response after two doses of the coronavirus vaccine.

Israel’s Medorion uses behavioral intelligence software to provide health insurers with an in-depth understanding of their plan members. It helps the companies retain customers by addressing members’ needs, improving medical conditions and helping members balance health against cost.

Israel’s Cardiac Success is developing a transcatheter ventricular repair device for heart failure patients. The “V-sling” system aims to transform invasive open-heart surgery on patients with Reduced Ejection Fraction (HFrEF) into a safe and effective minimally invasive transcatheter procedure.

Israel’s UltraSight (see previously) is starting clinical trials of its portable ultrasound device in the US and Israel. It will also be tested by Israeli astronaut Eytan Stibbe as part of the Israel Space Agency’s upcoming Rakia mission on the International Space Station.